Interstitial Cystitis Market Size in 7MM was ~USD 3 Billion in 2024 and it is expected to grow by 2034, estimates DelveInsight

DelveInsight's " Interstitial Cystitis Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Interstitial Cystitis, historical and forecasted epidemiology, as well as the Interstitial Cystitis Market Trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Discover Key Insights into the Interstitial Cystitis Market with DelveInsight's In-Depth Report @ Interstitial Cystitis Treatment Market Size- https://www.delveinsight.com/sample-request/interstitial-cystitis-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Interstitial Cystitis Market Report
• On 22 September 2025, Ono Pharmaceuticals Co. Ltd announced a Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Hunner Type Interstitial Cystitis.
• In 2024, the prevalent cases of interstitial cystitis were approximately 11 million across the 7MM, reflecting its significant disease burden and the pressing need for improved diagnostic tools and more effective treatments.
• In 2024, interstitial cystitis cases in the EU4 and the UK were distributed as approximately 50% moderate, 35% mild, and 15% severe, indicating that moderate cases represent the largest share of the clinical burden.
• In 2024, the highest burden of interstitial cystitis in the US was seen in the 56-74 age group with approximately 900 thousand cases, followed by ~700 thousand cases in those aged 36-55, highlighting the growing impact among middle-aged and older adults.
• In 2024, females represented approximately 60% of interstitial cystitis cases in the US while males accounted for 40% cases. This gender disparity reflects a significantly higher disease burden among women, emphasizing the need for tailored research and treatment strategies.
• The leading Interstitial Cystitis Companies such as Vaneltix Pharma, Hyloris Pharma, Ono Pharmaceutical, Seikagaku Corporation, Imbrium Therapeutics, ASKA Pharmaceutical, and others
• Promising Interstitial Cystitis Therapies such as ALENURA (Lidocaine + Heparin), ONO-1110, SI-722, Sunobinop (V117957), AKP-021, and others.

Stay ahead in the Interstitial Cystitis Therapeutics Market with DelveInsight's Strategic Report @ Interstitial Cystitis Market Outlook- https://www.delveinsight.com/sample-request/interstitial-cystitis-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Interstitial Cystitis Epidemiology Segmentation in the 7MM
• Interstitial Cystitis Prevalent Cases
• Total Interstitial Cystitis Diagnosed Prevalent Cases
• Interstitial Cystitis Age-specific Cases
• Interstitial Cystitis Gender-specific Cases
• Interstitial Cystitis Severity-specific Cases
• Interstitial Cystitis Type-specific Cases
• Total Interstitial Cystitis Treated Cases

Download the report to understand which factors are driving Interstitial Cystitis epidemiology trends @ Interstitial Cystitis Prevalence- https://www.delveinsight.com/sample-request/interstitial-cystitis-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Interstitial Cystitis Marketed Therapies
• ELMIRON (pentosan polysulfate sodium): Johnson & Johnson
ELMIRON is a semi-synthetically produced heparin-like macromolecular carbohydrate derivative, which chemically and structurally resembles glycosaminoglycans. It is a white odorless powder, slightly hygroscopic and soluble in water to 50% at pH 6. ELMIRON is supplied in white opaque hard gelatin capsules containing 100 mg pentosane polysulfate sodium, microcrystalline cellulose, and magnesium stearate. It is formulated for oral use.

• ZYMSO (Dimethyl Sulfoxide): KYORIN Pharmaceuticals
ZYMSO is an intravesical solution containing 50% dimethyl sulfoxide (DMSO). ZYMSO offers a targeted, non-systemic option for patients with refractory Hunner-type interstitial cystitis. By administering high-concentration DMSO directly into the bladder, it delivers potent local anti-inflammatory and analgesic effects with a known safety profile.

Interstitial Cystitis Emerging Therapies
• ALENURA (Lidocaine + Heparin): Vaneltix Pharma/Hyloris Pharma
ALENURA is a combination product of the glycosaminoglycan heparin and alkalinized lidocaine, which provides immediate pain relief to patients experiencing acute painful episodes of interstitial cystitis. ALENURA is supplied as a prefilled syringe for intravesicular installation into the bladder for on-demand relief of acute pain episodes.

Interstitial Cystitis Companies
Vaneltix Pharma, Hyloris Pharma, Ono Pharmaceutical, Seikagaku Corporation, Imbrium Therapeutics, ASKA Pharmaceutical, and others.

Get In-Depth Knowledge on Interstitial Cystitis Market Trends and Forecasts with DelveInsight @ Interstitial Cystitis Therapeutics Market Size- https://www.delveinsight.com/sample-request/interstitial-cystitis-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Interstitial Cystitis Market Report
• Coverage- 7MM
• Forecast Period- 2025-2034
• Interstitial Cystitis Companies- Vaneltix Pharma, Hyloris Pharma, Ono Pharmaceutical, Seikagaku Corporation, Imbrium Therapeutics, ASKA Pharmaceutical, and others.
• Interstitial Cystitis Therapies- ALENURA (Lidocaine + Heparin), ONO-1110, SI-722, Sunobinop (V117957), AKP-021, and others.
• Interstitial Cystitis Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Interstitial Cystitis Unmet Needs, KOL's views, Analyst's views, Interstitial Cystitis Market Access and Reimbursement

Unlock Strategic Insights with DelveInsight's Comprehensive Interstitial Cystitis Market Report @ Interstitial Cystitis Market Drivers and Barriers- https://www.delveinsight.com/sample-request/interstitial-cystitis-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Key Insights
2. Report Introduction
3. Interstitial Cystitis Market Overview at a Glance
4. Epidemiology and Market Methodology
5. Executive Summary
6. Key Events
7. Disease Background and Overview
8. Treatment and Management
9. Epidemiology and Patient Population
10. Patient Journey
11. Marketed Therapies
12. Emerging Therapies
13. Interstitial Cystitis - Seven Major Market Analysis
14. KOL Views
15. SWOT Analysis
16. Unmet Needs
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.